Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Triple-negative breast cancer--current status and future directions.
Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Gluz O, et al. Among authors: liedtke c. Ann Oncol. 2009 Dec;20(12):1913-27. doi: 10.1093/annonc/mdp492. Epub 2009 Nov 9. Ann Oncol. 2009. PMID: 19901010 Free article. Review.
Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.
Karn T, Pusztai L, Ruckhäberle E, Liedtke C, Müller V, Schmidt M, Metzler D, Wang J, Coombes KR, Gätje R, Hanker L, Solbach C, Ahr A, Holtrich U, Rody A, Kaufmann M. Karn T, et al. Among authors: liedtke c. Eur J Cancer. 2012 Jan;48(1):12-23. doi: 10.1016/j.ejca.2011.06.025. Epub 2011 Jul 7. Eur J Cancer. 2012. PMID: 21741824
A clinically relevant gene signature in triple negative and basal-like breast cancer.
Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Müller V, Holtrich U, Kaufmann M. Rody A, et al. Among authors: liedtke c. Breast Cancer Res. 2011 Oct 6;13(5):R97. doi: 10.1186/bcr3035. Breast Cancer Res. 2011. PMID: 21978456 Free PMC article.
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.
Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L. Kaufmann M, et al. Among authors: liedtke c. Ann Surg Oncol. 2012 May;19(5):1508-16. doi: 10.1245/s10434-011-2108-2. Epub 2011 Dec 23. Ann Surg Oncol. 2012. PMID: 22193884
Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.
Karn T, Pusztai L, Holtrich U, Iwamoto T, Shiang CY, Schmidt M, Müller V, Solbach C, Gaetje R, Hanker L, Ahr A, Liedtke C, Ruckhäberle E, Kaufmann M, Rody A. Karn T, et al. Among authors: liedtke c. PLoS One. 2011;6(12):e28403. doi: 10.1371/journal.pone.0028403. Epub 2011 Dec 29. PLoS One. 2011. PMID: 22220191 Free PMC article.
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.
Witzel I, Loibl S, von Minckwitz G, Eidtmann H, Fehm T, Khandan F, Schmatloch S, Hauschild M, Bischoff J, Fasching PA, Mau C, Schem C, Rack B, Meinhold-Heerlein I, Liedtke C, Karn T, Huober J, Zu Eulenburg C, Issa-Nummer Y, Untch M, Müller V. Witzel I, et al. Among authors: liedtke c. Br J Cancer. 2012 Sep 4;107(6):956-60. doi: 10.1038/bjc.2012.353. Epub 2012 Aug 14. Br J Cancer. 2012. PMID: 22892393 Free PMC article. Clinical Trial.
280 results